补肾化瘀壮骨方联合瑞舒伐他汀治疗老年骨质疏松性椎体压缩性骨折临床研究

Clinical Study on Bushen Huayu Zhuanggu Prescription Combined with Rosuvastatin for Senile Osteoporotic Vertebral Compression Fractures

目的:观察补肾化瘀壮骨方联合瑞舒伐他汀治疗老年骨质疏松性椎体压缩性骨折(OVCF)的临床疗效。方法:选取100例老年OVCF患者,随机分为观察组与对照组,每组50例。2组均进行经皮椎体成形术,对照组术后予口服瑞舒伐他汀钙片治疗,观察组予口服瑞舒伐他汀钙片联合补肾化瘀壮骨方治疗,2组均连续治疗3个月。对比2组治疗前后L1～4骨密度、骨矿含量及骨代谢指标[I型胶原交联氨基端肽(NTXI)、I型胶原交联羧基端肽(CTXI)、血骨钙素(BGP)、骨特异性碱性磷酸酶(BAP)]水平,对比2组治疗前后视觉模拟评分法(VAS)评分、Oswestry功能障碍指数及椎体功能。结果:治疗后,2组L1～4骨密度值及骨矿含量均较治疗前上升(P <0.05),观察组L1～4骨密度值及骨矿含量均高于对照组(P <0.05)。治疗后,2组NTXI、CTXI、BGP、BAP含量均较治疗前下降(P <0.05),观察组NTXI、CTXI、BGP、BAP含量均低于对照组(P <0.05)。治疗后,2组VAS评分及Oswestry功能障碍指数均较治疗前下降(P <0.05);观察组VAS评分及Oswestry功能障碍指数均低于对照组(P <0.05)。治疗后,2组椎体前缘高度均较治疗前升高(P <0.05),Cobb角均较治疗前缩小(P <0.05),椎管侵占率均较治疗前降低(P <0.05);观察组椎体前缘高度高于对照组(P <0.05),Cobb角小于对照组(P <0.05),椎管侵占率低于对照组(P <0.05)。结论:对于老年OVCF患者,经皮椎体成形术后采用补肾化瘀壮骨方联合瑞舒伐他汀钙片治疗,可提高患者的骨密度、骨矿含量,改善椎体功能,促进康复。

Objective:To observe the clinical effect of Bushen Huayu Zhuanggu prescription combined with rosuvastatin for senile osteoporotic vertebral compression fractures(OVCF).Methods:Selected 100 cases of senile patients with OVCF,and divided them into the observation group and the control group randomly,50 cases in each group.Both groups received percutaneous vertebral plastic operation.The control group received the oral administration of rosuvastatin tablets,while the observation group received Bushen Huayu Zhuanggu prescription combined with rosuvastatin.The treatment for both groups lasted for 3 months.Compared the levels of bone mineral density,bone mineral content in L1~4 and bone metabolic markers[cross-linked N-telopeptide of type I collagen(NTXI),C-terminal telopeptide of type I collagen(CTXI),bone glaprotein(BGP),bone-specific alkaline phosphatase(BAP)]of both groups before and after treatment,and compared scores of visual analogue scale(VAS),Oswestry disability index and vertebral function in both groups before and after treatment.Results:After treatment,the bone mineral density and content in L1~4 in both groups were higher than those before treatment(P<0.05),and both bone mineral density and content in L1~4 in the observation group were higher than those in the control group(P<0.05).After treatment,the contents of NTXI,CTXI,BGP and BAP in both groups were all lower than those before treatment(P<0.05),and the contents of NTXI,CTXI,BGP and BAP in the observation group were all lower than those in the control group(P<0.05).After treatment,the scores of VAS and Oswestry disability index in both groups were lower than those before treatment(P<0.05),and the scores of VAS and Oswestry disability index in the observation group were lower than those in the control group(P<0.05).After treatment,the anterior vertebral height in both groups was higher than that before treatment(P<0.05),Cobb angle was smaller than that before treatment(P<0.05),and ratio of spinal canal encroachment was lower than that before treatment(P<0.05);the anterior vertebral height in the observation group was higher than that in the control group(P<0.05),Cobb angle was smaller than that in the control group(P<0.05),and ratio of spinal canal encroachment was lower than that in the control group(P<0.05).Conclusion:The application of Bushen Huayu Zhuanggu prescription combined with rosuvastatin for senile patients with OVCF after undergoing percutaneous vertebral plastic operation can increased both bone mineral density and content of patients,improve vertebral function and promote recovery.